top of page

The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-

Philip Chaikin, PharmD,MD, FCP
Jan 26, 2018
1 min read

Chaikin-2017-The_Journal_of_Clinical_Pharmacologyprintversion _DOWNLOAD

Commentaires

Featured Posts

PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH

A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201

The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-

Life Sciences: The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in

Recent Posts

Successful Outcome in Contract Litigation

PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH

A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201

The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-

Life Sciences: The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in

Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors

Archive

Search By Tags

Follow Us

bottom of page